CAJ | 학술논문

目的探讨皮内注射甲基强的松龙联合口服伐昔洛韦治疗带状疱疹疗效.方法 60例带状疱疹患者随机分为皮内注射甲基强的松龙、联合口服伐昔洛韦组(A组,n =30);口服伐昔洛韦组(B组,n=30).治疗后随访,对比分析两组疱疹、疼痛评价指标、带状疱疹后遗痛发生率、综合疗效方面差异.结果两组患者基线特征相似.A组止疱时间、结痂时间、疼痛强度、疼痛缓解时间短于B组.30天随访,A组带状疱疹后遗神经痛发生率低于B组,60天、90天随访差异无统计学意义.综合疗效比较,A组总有效率为86.7％,B组总有效率为63.3％,A组优于B组.结论皮内注射甲基强的松龙联合口服伐昔洛韦治疗带状疱疹效果优于单用伐昔洛韦治疗,能够缩短病程,降低带状疱疹后遗神经痛的发生.
목적 탐토피내주사갑기강적송룡연합구복벌석락위치료대상포진료효.방법 60례대상포진환자수궤분위피내주사갑기강적송룡、연합구복벌석락위조(A조,n =30);구복벌석락위조(B조,n=30).치료후수방,대비분석량조포진、동통평개지표、대상포진후유통발생솔、종합료효방면차이.결과 량조환자기선특정상사.A조지포시간、결가시간、동통강도、동통완해시간단우B조.30천수방,A조대상포진후유신경통발생솔저우B조,60천、90천수방차이무통계학의의.종합료효비교,A조총유효솔위86.7％,B조총유효솔위63.3％,A조우우B조.결론 피내주사갑기강적송룡연합구복벌석락위치료대상포진효과우우단용벌석락위치료,능구축단병정,강저대상포진후유신경통적발생.
Objective To investigate the clinical efficacy of oral valaciclovir plus intradermal injection of methylprednisolone for the treatment of herpes zoster patients.Methods Sixty herpes zoster patients were randomly divided into two groups as follow:Group A:30 patients received oral valaciclovir plus intradermal injection of methylprednisolone,and Group B:30 patients treated with oral valaciclovir.And the following indicators,including herpes evaluation index,pain rating index,the incidence of postherpetic neuralgia,and comprehensive therapeutic effect were compared between the two groups after treatment.Results The baseline characteristics were comparable between Group A and B.The time to cessation of new lesion formation,complete rash crusting,cessation of pain and pain intensity after the treatment in Group A were significantly superior to those in group B.And the incidence of postherpetic neuralgia in Group A was significantly lower than that of Group B at 30 days of follow-up.However,no significant difference was found between the two groups at 60 and 90 days of follow-up.Overall,the total clinical effective rate of Group A (86.7 ％) was better than Group B (63.3 ％).Conclusion The treatment of oral valaciclovir plus intradermal injection of methylprednisolone was superior to oral valaciclovir in improving the clinical symptoms of HZ patients and reducing the incidence of postherpetic neuralgia.